Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability

医学 耐受性 药代动力学 安慰剂 生物利用度 不利影响 队列 药理学 随机对照试验 冲刷 内科学 胃肠病学 病理 替代医学
作者
Michael R. Hodges,Eric Ople,Karen Joy Shaw,Robert S. Mansbach,Sjoerd P. van Marle,Ewoud‐Jan van Hoogdalem,William G. Kramer,Pamela Wedel
出处
期刊:Open Forum Infectious Diseases [Oxford University Press]
卷期号:4 (suppl_1): S534-S534 被引量:46
标识
DOI:10.1093/ofid/ofx163.1390
摘要

APX001 is a first-in-class, intravenous (IV) and oral (PO) broad-spectrum antifungal agent in clinical development for the treatment of invasive fungal infections (IFIs) due to Candida, Aspergillus and rare molds. The active moiety APX001A inhibits Gwt1, an early step in glycosylphosphatidylinositol (GPI) anchor biosynthesis. Excellent in vivo efficacy has been demonstrated in murine models of IFIs with APX001A AUC0-24 target exposures ~ 80 µg.hours/mL. Eight subjects in Cohort 1a were randomized in a 6:2 ratio to receive APX001 or placebo. Single doses of IV 200 mg were infused over 3 hours followed by single (tablet) doses of 100, 300, and 500 mg, each separated by a 14-day washout period. Ten subjects in Cohort 1b were randomized in a 8:2 ratio to receive either APX001 or placebo. A single PO (tablet) dose of 400 mg was administered under fed and fasted conditions, each separated by a 14-day washout period. MAD Cohorts 2 and 3 were comprised of eight subjects randomized in a 6:2 ratio to receive APX001 or placebo. Subjects received PO (tablet) doses of 500 and 1000 mg daily for 14 days. Pharmacokinetic (PK) parameters for APX001A in plasma were calculated using non-compartmental analysis. Safety monitoring and intense PK sampling occurred throughout the trial. A safety committee reviewed the PK and safety data to determine dose escalation steps. Plasma exposure to APX001A was linear, dose proportional with low intersubject variability and a half-life of ~2.5 days. Accumulation of APX001A was observed in the MAD cohorts. After 14 days of dosing at 500 and 1000 mg AUC0-24 were 192 and 325 µg.hours/mL, respectively. The oral bioavailability was >90%. Administration of APX001 with a high fat, high calorie meal had no effect on the rate or extent of absorption. APX001 was well tolerated across all doses with no clinically significant adverse events observed. All subjects completed dosing. There were no dose limiting toxicities. Most of the adverse events (AEs) were mild, transient and required no treatment. The most common AE was headache. APX001 given orally is highly bioavailable, has no food effect and can exceed target exposures of APX001A for efficacy against Candida and Aspergillus at doses that are safe and well tolerated. M. R. Hodges, Amplyx Pharmaceuticals: Employee, Salary; E. Ople, Amplyx Pharmaceuticals Inc.: Employee, Salary; K. J. Shaw, Amplyx Pharmaceuticals Inc.: Employee, Salary; R. Mansbach, Amplyx Pharmaceuticals Inc.: Consultant, Consulting fee; S. P. Van Marle, PRA Health Sciences: Employee, Salary; E. J. Van Hoogdalem, PRA Health Sciences: Employee, Salary; W. Kramer, Amplyx Pharmaceuticals Inc.: Consultant, Consulting fee; P. Wedel, Amplyx Pharmaceuticals Inc.: Employee, Salary

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
须臾完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
xxxxxx发布了新的文献求助10
1秒前
wh完成签到,获得积分10
1秒前
2秒前
2秒前
明天瘦到88完成签到 ,获得积分10
2秒前
漫柯完成签到,获得积分10
2秒前
3秒前
3秒前
dukejoe完成签到,获得积分10
3秒前
庾北瑶完成签到 ,获得积分10
3秒前
万能图书馆的应助被平常心采纳,获得10
3秒前
醒醒发布了新的文献求助10
3秒前
Eraser完成签到,获得积分10
3秒前
ililiiris发布了新的文献求助10
3秒前
失眠世平完成签到 ,获得积分10
4秒前
lucky完成签到,获得积分10
4秒前
4秒前
pierniao发布了新的文献求助10
4秒前
柚子完成签到 ,获得积分10
4秒前
4秒前
赘婿的应助被科研小白采纳,获得10
5秒前
李健的小迷弟的应助被zoya采纳,获得10
5秒前
Maestro_S发布了新的文献求助50
5秒前
古古怪界丶黑大帅完成签到,获得积分10
5秒前
5秒前
hao发布了新的文献求助10
5秒前
5秒前
Renwang发布了新的文献求助10
6秒前
6秒前
马騳骉完成签到,获得积分10
6秒前
6秒前
ccccyyy完成签到,获得积分10
6秒前
单薄铅笔完成签到,获得积分10
7秒前
吴洲凤完成签到,获得积分10
7秒前
hbutsj完成签到,获得积分10
7秒前
pp完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159663
求助须知:如何正确求助?哪些是违规求助? 9555211
关于积分的说明 21725494
捐赠科研通 7749713
什么是DOI,文献DOI怎么找? 3427292
关于科研通互助平台的介绍 2552372
邀请新用户注册赠送积分活动 2471628